Unleashing the Power of Innate Agonist Precision Delivery to Tumors Through ADC Technology
- Exploring next-generation ADCs delivering innate agonist payloads with precision
- Explaining how targeted delivery ensures location-specific processing by tumor-resident phagocytic immune cells, leading to the strategic release of the payload
- Assessing how resulting robust activation of myeloid cells within the tumor microenvironment sets the stage for a potent adaptive anti-tumor immune response